密固达治疗绝经后骨质疏松患者的3年临床分析

发布时间：2018-03-27 08:53

本文选题：绝经后骨质疏松　切入点：唑来膦酸　出处：《中国骨质疏松杂志》2017年08期

【摘要】：目的分析绝经后骨质疏松患者在3年间每年输注1次唑来膦酸(商品名:密固达)后的疗效、安全性。方法回顾性分析2011年2月至2016年6月,青岛大学附属医院绝经后骨质疏松患者的住院或门诊诊疗记录,选取绝经后妇女、平均年龄62.5岁的骨质疏松患者入组。对照组36人,口服骨化醇及钙剂,研究组36人在服用骨化醇及钙剂的基础上分别在基线、12个月和24个月时各接受1次15 min唑来膦酸(5 mg)静脉滴注。观察所有患者至第36个月。通过对比两组各时期腰椎1-4、股骨颈、髋骨骨密度改变、疼痛评分、不良反应和新发骨折率,评价疗效及安全性。结果两组入组患者年龄、骨密度相似。治疗后研究组各部位的骨密度较对照组同时期显著增加(P0.01);研究组同部位骨密度高于前一时期的骨密度(P0.05);研究组治疗后各时期疼痛评分下降明显多于对照组(P0.05);研究组各时期疼痛评分低于前一时期(P0.05);研究组有更多的不良反应,第2、3次输注后不良反应较第1次明显减少;新发骨折数较对照组少。结论唑来膦酸注射液治疗能有效提升骨密度,且3次输注后骨密度呈递增趋势;不良反应多在每次治疗后前3天出现,但第2、3次治疗后不良反应明显少于第1次;输注3次唑来膦酸减少了新发骨折发生率。
[Abstract]:Objective to analyze the efficacy and safety of intravenous zoledronic acid (Zoledronic acid) once a year in postmenopausal patients with osteoporosis during 3 years. Methods from February 2011 to June 2016, the efficacy and safety of Zoledronic acid in postmenopausal osteoporosis patients were analyzed retrospectively. The records of postmenopausal osteoporosis patients in Qingdao University affiliated Hospital were recorded. Postmenopausal women with an average age of 62.5 years were selected into the group. 36 patients in the control group were treated by oral administration of osseol and calcium. On the basis of calcitonin and calcitonin, 36 patients in the study group were given 15 min zoledronate 5 mg intravenously at baseline, 12 and 24 months, respectively. All patients were observed to 36 months. The lumbar vertebrae 1-4, femoral neck, femoral neck were compared between the two groups. Hip bone mineral density change, pain score, adverse reaction and rate of new fracture, efficacy and safety were evaluated. After treatment, the BMD of each site in the study group was significantly higher than that in the control group at the same time, the BMD of the same site in the study group was higher than that in the previous period, and the pain score of the study group was significantly lower than that of the control group in each period after treatment. In the control group, the pain score in each period was lower than that in the previous period, and there were more adverse reactions in the study group. The number of new fractures was less than that of the control group. Conclusion Zoledronic acid injection can effectively enhance BMD, and the BMD increases gradually after 3 times of infusion. Most of the adverse reactions occurred 3 days before each treatment, but the adverse reactions after the second and third treatment were significantly less than that of the first, and the incidence of new fractures was reduced by the infusion of 3 times of zoledronic acid.
【作者单位】：青岛大学附属医院内分泌科;
【分类号】：R580

【相似文献】